Skip to main content
SINSIN PHARMACEUTICAL Co., LTD. logo

SINSIN PHARMACEUTICAL Co., LTD. — Investor Relations & Filings

Ticker · 002800 ISIN · KR7002800001 KO Manufacturing
Open in API
Filings indexed 175 across all filing types
Latest filing 2024-03-06 AGM Information
Country KR South Korea
Listing KO 002800

About SINSIN PHARMACEUTICAL Co., LTD.

https://sinsin2002.tradekorea.com/

Sinsin Pharmaceutical Co., Ltd. is a pharmaceutical company that specializes in the development, manufacturing, and marketing of over-the-counter (OTC) medicines for external use. The company's core product portfolio centers on topical anti-inflammatory and analgesic drugs, including its widely recognized brand of pain relief patches, "SINSIN PAS," alongside various sprays and lotions. The company also produces a diverse range of consumer healthcare items such as mosquito repellents, wound care products like surgical plasters and healing bands, anti-mycotic treatments, and other dermatological preparations for both domestic and overseas markets.

Recent filings

Filing Released Lang Actions
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Sinsin Pharmaceutical. It contains the agenda for the upcoming Annual General Meeting (AGM), including reports on audit, business operations, internal accounting, and proposals for financial statement approval, director appointments, and remuneration limits. It also includes detailed management information and financial statements as part of the meeting materials. This document is a standard proxy statement/notice for an AGM, which falls under the 'Proxy Solicitation & Information Statement' category.
2024-03-06 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used by companies to solicit proxies from shareholders for an upcoming Annual General Meeting (AGM). It contains details about the meeting, agenda items (such as approval of financial statements and election of directors), and proxy voting procedures. This fits the definition of a Proxy Solicitation & Information Statement (PSI).
2024-03-06 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Shinshin Pharmaceutical regarding the decision to pay cash dividends. It specifies the dividend amount per share, the dividend record date, the total dividend amount, and the scheduled date for the general meeting of shareholders to approve the dividend. This aligns perfectly with the definition of a 'Notice of Dividend Amount' (DIV).
2024-02-06 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Shinshin Pharmaceutical. It details the date, location, and agenda items for the upcoming Annual General Meeting, including the approval of financial statements, election of directors and auditors, and remuneration limits. This type of document is a standard proxy solicitation and information statement provided to shareholders to inform them of meeting details and request their participation/votes.
2024-02-06 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a formal notice regarding the closure of the shareholder register and the setting of a record date for the purpose of determining shareholders eligible to vote at the upcoming 61st Annual General Meeting. This type of regulatory disclosure, which informs shareholders of administrative actions related to meeting preparation, is classified as a general regulatory filing.
2023-12-15 Korean
투자판단관련주요경영사항(임상시험계획승인신청)(불면증 환자의 단기치료제 SS262의 임상 1상 임상시험계획(IND) 승인신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Shinshin Pharmaceutical regarding the submission of an Investigational New Drug (IND) application for a Phase 1 clinical trial. It details the clinical trial name, purpose, and regulatory status. Since it is a specific regulatory announcement regarding business operations and clinical trial progress that does not fit into financial reporting or corporate governance categories, it is classified as a Regulatory Filing (RNS).
2023-11-15 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.